Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eyetech Pharmaceuticals
With
Pfizer
This study will consist of 3 phases: a screening phase which will last up to two weeks, a confirmation phase which will last one day, and a randomization phase (the patient will be assigned by chance to a study group in this phase) which will last approximately 52 weeks.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CRVO must have occurred within the past 6 months and be associated with macular edema determined by OCT.
Vision in the study eye corresponding to between approximately 20/50 to 20/400 and better than or equal to approximately 20/200 in the fellow eye.
You may not be if
Presence of signs of old branch retinal vein occlusion (BRVO) or CRVO in the study eye or any other retinal vascular disease including diabetic retinopathy.
Vitreous hemorrhage except breakthrough hemorrhage from intraretinal hemorrhage.
Prior pan retinal photocoagulation (PRP) or sector scatter photocoagulation.
Clareo Health | Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
